JC virus-induced progressive multifocal leukoencephalopathy

Future Virology

Volumn 5, Issue 3, 2010, Pages 313-323

  Saribaş, A Sami ^a   Özdemir, Ahmet ^a   Lam, Cathy ^a   Safak, Mahmut ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Efalizumab; JC virus; Lifecycle; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; Replication; Rituximab

Indexed keywords

CIDOFOVIR; CYTARABINE; EFALIZUMAB; HEPARIN; INTERFERON; LEFLUNOMIDE; MEFLOQUINE; NATALIZUMAB; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; RITUXIMAB; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; CARCINOGENESIS; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOCYTOCHEMISTRY; JC VIRUS; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEIC ACID ANALYSIS; OLIGODENDROGLIA; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIRION; VIROGENESIS; VIRUS GENOME; VIRUS REACTIVATION; VIRUS REPLICATION;

JC POLYOMAVIRUS;

EID: 77952258768     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.12     Document Type: Review

References (111)

1. Hallervorden J: Eigennetige und nicht rubriziebare prozesse. In: Handbuch der Geiteskranheiten (Volume 2), Die Anatomie der Phychosen. Springer, Berlin, Germany (1930).
2. Astrom KE, Mancell EL, Richardson EPJ: Progressive multifocal encephalopathy: a hitherto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 81, 99-111 (1958).
3. Cavanaugh JB, Greenbaum D, Marchall A, Rubinstein L: Cerebral demyelination associated with disorder of the reticuloendothelial system. Lancet 2, 524-529 (1959).
4. ZuRhein GM, Chou SM: Particles resembling papovavirus in human cerebral demyelinating disease. Science 148, 1477-1479 (1965).
5. ZuRhein GM: Association of papovavirions with a human demyelination disease (progressive multifocal leukoencephalopathy). Prog. Med. Virol. 11, 185-248 (1969).
6. Padgett BL, Zu Rhein GM, Walker DL, Echroade R, Dessel B: Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1, 1257-1260 (1971).
7. Frisque RJ, Bream GL, Cannella MT: Human polyomavirus JC virus genome. J. Virol. 51, 458-469 (1984).
8. Gardner SD, Feild AM, Colleman DV, Hulme B: New human papovavirus (BK) isolated from urine after renal transplantation. Lancet 1, 1253-1257 (1971).
9. Berger JR, Concha M: Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J. Neurovirol. 1, 5-18 (1995).
10. Frisque RJ, White FA: The molecular biology of JC virus, causative agent of progressive multifocal leukoencephalopathy. In: Molecular Neurovirology. Roos RP (Ed.). Humana Press, NJ, USA (1992).
11. Major EO, Amemiya K, Tornatore CS et al.: Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 5, 49-73 (1992).
12. Power C, Gladden JG, Halliday W et al.: AIDS-and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54, 743-746 (2000).
13. Antinori A, Ammassari A, Giancola ML et al.: Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J. Neurovirol. 7, 323-328 (2001).
14. Chowdhury M, Kundu M, Khalili K: GA/GC-rich sequence confers Tat responsiveness to human neurotropic virus promoter, JCVL, in cells derived from central nervous system. Oncogene 8, 887-892 (1993).
15. Chowdhury M, Taylor JP, Chang CF et al.: Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 Tat. J. Virol. 66, 7355-7361 (1992).
16. Chowdhury M, Taylor JP, Tada H et al.: Regulation of the human neurotropic virus promoter by JCV-T antigen and HIV-1 tat protein. Oncogene 5, 1737-1742 (1990).
17. Tada H, Rappaport J, Lashgari M et al.: Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc. Natl Acad. Sci. USA 87, 3479-3483 (1990).
18. Cullen BR: The HIV-1 tat protein: as RNA specific processivity factor. Cell 63, 655-657 (1990).
19. Frankel AD: Activation of HIV transcription by Tat. Curr. Opin. Genes Dev. 2, 293-298 (1992).
20. Krachmarov CP, Chepenik LG, Barr-Vagell S et al.: Activation of the JC virus Tat-responsive transcriptional control element by association of the Tat protein of human immunodeficiency virus 1 with cellular protein Pur-a. Proc. Natl Acad. Sci. USA 93, 14112-14117 (1996).
21. Del Valle L, Croul S, Morgello S et al.: Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J. Neurovirol. 6, 221-228 (2000).
22. Frankel AD, Papo CO: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55(6), 1189-1193 (1988).
23. Nukuzuma S, Kameoka M, Sugiura S et al.: Archetype JC virus efficiently propagates in kidney-derived cells stably expressing HIV-1 Tat. Microbiol. Immunol. 53, 621-628 (2009).
24. Stettner MR, Nance JA, Wright CA et al.: SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the Tat protein of human immunodeficiency virus type 1. J. Gen. Virol. 90, 2005-2014 (2009).
25. Genes P, Jett M, Bernton EV et al.: Cytokines and arachidonic metabolites produced during the human immunodeficiency virus (HIV)-infected macrophage-astroglia interaction: implications for the neuropathogenesis of HIV disease. J. Exp. Med. 176, 1703-1718 (1992).
26. Gordon J, Khalili K: The human polyomavirus, JCV, and neurological diseases (review). Int. J. Mol. Med. 1, 647-655 (1998).
27. Walker DL, Padgett BL, Zu Rhein GM et al.: Human papovavirus (JC): induction of brain tumors in hamsters. Science 181, 674-676 (1973).
28. Brooks BR, Walker DL: Progressive multifocal encephalopathy. Neurol. Clin. 2, 299-313 (1984).
29. Thomson RA, Jones M: Remission in progressive multifocal leukoencephalopathy. Neurology 18(3), 308 (1968).
30. Zoltick PW, Mayreddy RP, Chang CF et al.: Isolation and characterization of a type II JC virus from a brain biopsy of a patient with PML. J. Neurovirol. 1, 307-315 (1995).
31. Berger JR: Progressive multifocal leukoencephalopathy. Curr. Treat. Options Neurol. 2, 361-368 (2000).
32. Berger JR, Kaszovitz B, Post MJ, Dickinson G: Progressive multifocal leukoencephalopathy associated with immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann. Intern. Med. 107, 78-87 (1987).
33. Cinque P, Vago L, Dahl H et al.: Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10, 951-958 (1996). (Pubitemid 26252624)
34. Aksamit AJ, Sever JL, Major EO: Progressive multifocal leukoencephalopathy: JC virus detection by in situ hybridization compared with immunohistochemistry. Neurology 36, 499-504 (1986).
35. Ryschkewitsch C, Jensen P, Hou J et al.: Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J. Virol. Methods 121, 217-221 (2004).
36. Wang Y, Kirby JE, Qian Q: Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J. Med. Microbiol. 58, 253-255 (2009).
37. Brenan M, Parish CR: Modification of lymphocyte migration by sulfated polysaccharides. Eur. J. Immunol. 16, 423-430 (1986).
38. Houff SA, Major EO, Katz DA et al.: Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N. Engl. J. Med. 318, 301-305 (1988).
39. Dubois V, Dutronc H, Lafon ME et al.: Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J. Clin. Microbiol. 35, 2288-2292 (1997).
40. Koralnik IJ, Schmitz JE, Lifton MA et al.: Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. J. Neurovirol. 5, 430-435 (1999).
41. Monaco MC, Atwood WJ, Gravell M et al.: JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol. 70, 7004-7012 (1996).
42. Monaco MC, Shin J, Major EO: JC virus infection in cells from lymphoid tissue. Dev. Biol. Stand. 94, 115-122 (1998).
43. Epker JL, van Biezen P, van Daele PL et al.: Progressive multifocal leukoencephalopathy, a review and an extended report of five patients with different immune compromised states. Eur. J. Intern. Med. 20, 261-267 (2009).
44. Brickelmaier M, Lugovskoy A, Kartikeyan R et al.: Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother. 53, 1840-1849 (2009).
45. Lynch KJ, Frisque RJ: Identification of critical elements within the JC virus DNA replication origin. J. Virol. 64, 5812-5822 (1990).
46. Lynch KJ, Frisque RJ: Factors contributing to the restricted DNA replicating activity of JC virus. Virology 180, 306-317 (1991).
47. Darbinyan A, Darbinian N, Safak M et al.: Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene 21, 5574-5581 (2002).
48. Yogo Y, Kitamura T, Sugimoto C et al.: Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J. Virol. 64, 3139-3143 (1990).
49. Sariyer IK, Khalili K, Safak M: Dephosphorylation of JC virus agnoprotein by protein phosphatase 2A: inhibition by small t antigen. Virology 375(2), 464-479.
50. Khalili K, Sariyer IK, Safak M: Small tumor antigen of polyomaviruses: role in viral life cycle and cell transformation. J. Cell. Physiol. 215, 309-319 (2008).
51. Howe AK, Gaillard S, Bennett JS et al.: Cell cycle progression in monkey cells expressing simian virus 40 small t antigen from adenovirus vectors. J. Virol. 72, 9637-9644 (1998).
52. Rundell K, Gaillard S, Porras A: Small-t and large-T antigens cooperate to drive cell proliferation. Dev. Biol. Stand. 94, 289-295 (1998).
53. Frisque RJ: Structure and function of JC virus T́ proteins. J. Neurovirol. 7, 293-297 (2001).
54. Chang D, Cai X, Consigli RA: Characterization of the DNA binding properties of polyomavirus capsid protein. J. Virol. 67, 6327-6331 (1993).
55. Huang YL, Wang M, Ou WC et al.: Analysis of DNA-binding activity of the JC virus minor capsid protein VP2. J. Neurovirol. 9(Suppl. 1), 21-24 (2003).
56. Saji H, Toi M, Saji S et al.: Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 190, 191-197 (2003).
57. Sariyer IK, Akan I, Palermo V et al.: Phosphorylation mutants of JC virus agnoprotein are unable to sustain the viral infection cycle. J. Virol. 80, 3893-3903 (2006).
58. Myhre MR, Olsen GH, Gosert R et al.: Clinical polyomavirus BK variants with agnogene deletion are non-functional but rescued by trans-complementation. Virology 398(1), 12-20 (2010).
59. Johannessen M, Myhre MR, Dragset M et al.: Phosphorylation of human polyomavirus BK agnoprotein at Ser-11 is mediated by PKC and has an important regulative function. Virology 379, 97-109 (2008).
60. Bollag B, Chuke WF, Frisque RJ: Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: identification of sequences important for efficient transformation. J. Virol. 63, 863-872 (1989).
61. Haggerty S, Walker DL, Frisque RJ: JC virus-simian virus 40 genomes containing heterologous regulatory signals and chimeric early regions: identification of regions restricting transformation by JC virus. J. Virol. 63, 2180-2190 (1989).
62. Safak M, Gallia GL, Ansari SA et al.: Physical and functional interaction between the Y-box binding protein YB-1 and human polyomavirus JC virus large T antigen. J. Virol. 73, 10146-10157 (1999).
63. Safak M, Gallia GL, Khalili K: A 23-bp sequence element from human neurotropic JC virus is responsive to NF-kB subunits. Virology 262, 178-189 (1999).
64. Safak M, Gallia G, Khalili K: Reciprocal interaction between two cellular proteins, Pura and YB-1, modulates transcriptional activity of JCVCY in glial cells. Mol. Cell. Biol. 19, 2712-2723 (1999).
65. Safak M, Barrucco R, Darbinyan A et al.: Interaction of JC virus agno protein with T antigen modulates transcription and replication of the viral genome in glial cells. J. Virol. 75, 1476-1486 (2001).
66. Kim J, Woolridge S, Biffi R et al.: Members of the AP-1 family, c-Jun and c-Fos, functionally interact with JC virus early regulatory protein large T antigen. J. Virol. 77, 5241-5252 (2003).
67. Sadowska B, Barrucco R, Khalili K et al.: Regulation of human polyomavirus JC virus gene transcription by AP-1 in glial cells. J. Virol. 77, 665-672 (2003). (Pubitemid 36005003)
68. Safak M, Major E, Khalili K: The Neurology of AIDS. Gendelman HE, Everall IP, Lipton SA, Swindells S (Eds). Oxford University Press, Oxford, UK 461-474 (2005).
69. White MK, Safak M, Khalili K: Regulation of gene expression in primate polyomaviruses. J. Virol. 83, 10846-10856 (2009).
70. Wegner M, Drolet DW, Rosenfeld MG: Regulation of JC virus by the POU-domain transcription factor Tst-1: implications for progressive multifocal leukoencephalopathy. Proc. Natl Acad. Sci. USA 90, 4743-4747 (1993).
71. Monaco MC, Sabath BF, Durham LC et al.: JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J. Virol. 75, 9687-9695 (2001).
72. Chang CF, Gallia GL, Muralidharan V et al.: Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence-specific single-stranded DNA-binding protein Pur-a. J. Virol. 70, 4150-4156 (1996).
73. Beggs AH, Frisque RJ, Scangos GA: Extinction of JC virus tumor-antigen expression in glial cell - fibroblast hybrids. Proc. Natl Acad. Sci. USA 85, 7632-7636 (1988).
74. Beggs AH, Miner JH, Scangos GA: Cell type-specific expression of JC virus T antigen in primary and established cell lines from transgenic mice. J. Gen. Virol. 71, 151-164 (1990).
75. Baker TS, Drak J, Bina M: The capsid of small papova viruses contains 72 pentameric capsomeres: direct evidence from cryo-electron-microscopy of simian virus 40. Biophys. J. 55, 243-253 (1989).
76. Ou WC, Wang M, Fung CY et al.: The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J. Gen. Virol. 80, 39-46 (1999).
77. Bina M, Ng SC, Blasquez V: Simian virus 40 chromatin interaction with the capsid proteins. J. Biomol. Struct. Dyn. 1, 689-704 (1983).
78. Chang D, Fung CY, Ou WC et al.: Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J. Gen. Virol. 78, 1435-1439 (1997).
79. Chen PL, Wang M, Ou WC et al.: Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Lett. 500, 109-113 (2001).
80. Sandalon Z, Oppenheim A: Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 237, 414-421 (1997).
81. Elphick GF, Querbes W, Jordan JA et al.: The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306, 1380-1383 (2004).
82. Gee GV, Tsomaia N, Mierke DF et al.: Modeling a sialic acid binding pocket in the external loops of JC virus VP1. J. Biol. Chem. 279, 49172-49176 (2004).
83. Pho MT, Ashok A, Atwood WJ: JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J. Virol. 74, 2288-2292 (2000).
84. Lashgari MS, Tada H, Amini S et al.: Regulation of JCVL promoter function: transactivation of JCVL promoter by JCV and SV40 early proteins. Virology 170, 292-295 (1989).
85. Seth P, Diaz F, Tao-Cheng JH et al.: JC virus induces nonapoptotic cell death of human central nervous system progenitor cell-derived astrocytes. J. Virol. 78, 4884-4891 (2004).
86. Richardson EP: Progressive multifocal encephalopathy. N. Engl. J. Med. 265, 815-823 (1961).
87. Rencic A, Gordon J, Otte J et al.: Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma. Proc. Natl Acad. Sci. USA 93, 7352-7357 (1996).
88. Del Valle L, Gordo J, Ferrante P, Khalili K: Human Polyomaviruses: Molecular and Clinical Perspectives. Khalili K (Ed.). John Wiley & Sons, Inc., NY, USA 409-430 (2001).
89. Krynska B, Del Valle L, Croul S et al.: Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc. Natl Acad. Sci. USA 96, 11519-11524 (1999).
90. Del Valle L, Enam S, Lara C et al.: Primary central nervous system lymphoma expressing the human neurotropic polyomavirus, JC virus, genome. J. Virol. 78, 3462-3469 (2004).
91. Del Valle L, Gordon J, Enam S et al.: Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J. Natl Cancer Inst. 94, 267-273 (2002).
92. Del Valle L, Azizi SA, Krynska B et al.: Reactivation of human neurotropic JC virus expressing oncogenic protein in a recurrent glioblastoma multiforme. Ann. Neurol. 48, 932-936 (2000).
93. Enam S, Del Valle L, Lara C et al.: Association of human polyomavirus JCV with colon cancer: evidence for interaction of viral T-antigen and b-catenin. Cancer Res. 62, 7093-7101 (2002).
94. Ricciardiello L, Laghi L, Ramamirtham P et al.: JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 119, 1228-1235 (2000).
95. Del Valle L, Baehring J, Lorenzana C et al.: Expression of a human polyomavirus oncoprotein and tumour suppressor proteins in medulloblastomas. Mol. Pathol. 54, 331-337 (2001).
96. Franks RR, Rencic A, Gordon J et al.: Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polymavirus early protein. Oncogene 12, 2573-2578 (1996).
97. Krynska B, Otte J, Franks R et al.: Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene 18, 39-46 (1999).
98. Gordon J, Del Valle L, Otte J et al.: Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice. Oncogene 19, 4840-4846 (2000).
99. Small JA, Scangos GA, Cork L et al.: The early region of human papovavirus JC induces dysmyelination in transgenic mice. Cell 46, 13-18 (1986).
100. Shollar D, Del Valle L, Khalili K et al.: JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors. Oncogene 23, 5459-5467 (2004).
101. White MK, Gordon J, Reiss K et al.: Human polyomaviruses and brain tumors. Brain Res. Brain Res. Rev. 50, 69-85 (2005).
102. London WT, Houff SA, Madden DL et al.: Brain tumors in owl monkeys inoculated with a human polyomavirus (JC virus). Science 201, 1246-1249 (1978).
103. London WT, Houff SA, McKeever PE et al.: Viral-induced astrocytomas in squirrel monkeys. Prog. Clin. Biol. Res. 105, 227-237 (1983).
104. Dyson N, Bernards R, Friend SH et al.: Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J. Virol. 64, 1353-1356 (1990).
105. Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35-47 (2010).
106. Langer-Gould A, Atlas SW, Green AJ et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375-381 (2005).
107. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon b-1a for multiple sclerosis. N. Engl. J. Med. 353, 369-374 (2005).
108. Van Assche G, Van Ranst M, Sciot R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
109. Chen Y, Bord E, Tompkins T et al.: Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361, 1067-1074 (2009).
110. Carson KR, Evens AM, Richey EA et al.: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113, 4834-4840 (2009).
111. Khalili K, White MK: Human demylinating disease and the polyomavirus JCV. Mult. Scler. 12, 133-142 (2006).